{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:03:22Z","timestamp":1793160202684,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"\n Importance<\/jats:title>\n Digitalis glycosides may be used as additional therapy in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or HF with reduced EF (HFrEF).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the effect of digitalis glycosides on clinical outcomes in patients with HFmrEF or HFrEF.<\/jats:p>\n <\/jats:sec>\n \n Data Sources and Study Selection<\/jats:title>\n PubMed was searched from inception to March 1, 2026, using medical subject headings and keywords related to digitalis glycosides and HF. The review was restricted to placebo-controlled randomized clinical trials including more than 1000 patients and articles published in the English language.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Data were extracted by 2 reviewers who followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Risk of bias was assessed with the Cochrane Risk of Bias tool (version 2). A fixed-effects model was used to estimate the hazard ratios (HRs) with 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the composite of time to cardiovascular death or first worsening HF event. Secondary outcomes included individual components of the composite outcome and time to all-cause death.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 3 studies met the inclusion criteria and included 9013 patients with HFmrEF or HFrEF (weighted mean age, 64.5 [weighted SD, 11.2] years; 22% female and 78% male). The composite outcome of cardiovascular death or first worsening HF event occurred in 1852 of 4510 patients (41%) in the digitalis glycoside group vs 2037 of 4503 patients (45%) in the placebo group (HR, 0.85 [95% CI, 0.80-0.90];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). First worsening HF event occurred in 1183 (26%) patients in the digitalis glycoside group vs 1474 (33%) patients in the placebo group (HR, 0.75 [95% CI, 0.69-0.81];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). There were 1224 cardiovascular events in the digitalis glycoside group vs 1224 in the placebo group (27% of participants in each group; HR, 0.99 [95% CI, 0.92-1.07];\n P<\/jats:italic>\n \u2009=\u2009.81) and there were 1466 vs 1497, respectively, all-cause deaths (32% of participants vs 33%; HR, 0.97 [95% CI, 0.90-1.04];\n P<\/jats:italic>\n \u2009=\u2009.41). There was no statistically significant heterogeneity by trial, type of digitalis glycoside treatment, or extent of background HF therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Treatment with digitalis glycosides was associated with a lower risk of the composite of cardiovascular death or first worsening HF event in patients with HFmrEF or HFrEF, mainly through a lower risk of worsening HF events. There was no statistically significant interaction with important study characteristics, including the extent of HF background therapy or type of digitalis glycosides treatment. These results suggest digitalis glycosides may be used as additional medical therapy to reduce worsening HF events in patients with HFmrEF or HFrEF.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.7886","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T12:30:11Z","timestamp":1778416211000},"page":"2029","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and Safety of Digitalis Glycosides in Heart Failure"],"prefix":"10.1001","volume":"335","author":[{"given":"Kevin","family":"Damman","sequence":"first","affiliation":[{"name":"University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Rienstra","sequence":"additional","affiliation":[{"name":"University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Mosterd","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands"},{"name":"Dutch Network for Cardiovascular Research, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert H. D.","family":"Voordes","sequence":"additional","affiliation":[{"name":"University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Bavendiek","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"36","key":"joi260047r1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"18","key":"joi260047r2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"8","key":"joi260047r3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure.","volume":"336","author":"Digitalis Investigation","year":"1997","journal-title":"N Engl J Med"},{"issue":"24","key":"joi260047r4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study.","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"issue":"5","key":"joi260047r5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"joi260047r6","doi-asserted-by":"publisher","first-page":"60A","DOI":"10.1016\/S0002-9149(88)80087-0","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).","volume":"62","author":"Swedberg","year":"1988","journal-title":"Am J Cardiol"},{"issue":"9169","key":"joi260047r7","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"joi260047r8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"21","key":"joi260047r9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"joi260047r10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"joi260047r11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/eurheartj\/ehs004","article-title":"Should we SHIFT our thinking about digoxin? observations on ivabradine and heart rate reduction in heart failure.","volume":"33","author":"Castagno","year":"2012","journal-title":"Eur Heart J"},{"issue":"6","key":"joi260047r12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0735-1097(02)01708-4","article-title":"Clinical benefits of low serum digoxin concentrations in heart failure.","volume":"39","author":"Adams","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"joi260047r13","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1093\/eurheartj\/ehad185","article-title":"Digitalis in heart failure: declining use and ongoing outcome trials.","volume":"44","author":"van Veldhuisen","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"joi260047r14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","article-title":"Digitoxin in patients with heart failure and reduced ejection fraction.","volume":"393","author":"Bavendiek","year":"2025","journal-title":"N Engl J Med"},{"key":"joi260047r15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04406-6","article-title":"Low-dose digoxin in heart failure with reduced or mildly reduced ejection fraction.","author":"Van Veldhuisen","journal-title":"Nat Med"},{"key":"joi260047r16","doi-asserted-by":"publisher","DOI":"10.1093\/ejhf\/xuag073","article-title":"Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.","author":"van der Meer","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"joi260047r17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF.","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"issue":"20","key":"joi260047r18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/eurheartj\/ehaf009","article-title":"2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention.","volume":"46","author":"J\u00fcni","year":"2025","journal-title":"Eur Heart J"},{"key":"joi260047r19","doi-asserted-by":"publisher","DOI":"10.1093\/ejhf\/xuaf002","article-title":"Digitalis\u2014back on centre stage for HFrEF.","author":"Bauersachs","journal-title":"Eur J Heart Fail"},{"issue":"9744","key":"joi260047r20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"10510","key":"joi260047r21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.","volume":"406","author":"Zannad","year":"2025","journal-title":"Lancet"},{"key":"joi260047r22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2026.1746467","article-title":"Cardiac glycosides in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.","volume":"13","author":"Wang","year":"2026","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"joi260047r23","first-page":"309","article-title":"Finerenone in heart failure with preserved ejection fraction: reply.","volume":"392","author":"Solomon","year":"2025","journal-title":"N Engl J Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2848972\/jama_damman_2026_oi_260047_1780943377.15725.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:00:48Z","timestamp":1781622048000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2848972"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.7886","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}